Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan T Chard

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2019
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumabJ William L Brown, Ferran Prados Carrasco, Arman Eshaghi, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Trials|December 8, 2025
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapyGioia Riboni-Verri, Christopher E McMurran, Trisha Mukherjee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 9, 2020
Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosisRuth Geraldes, Maciej Juryńczyk, Giordani Dos Passos, et al.
Multiple Sclerosis and Related Disorders|February 8, 2018
Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2016
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosisMatteo Pardini, Carole H Sudre, Ferran Prados, et al.
JAMA Neurology|December 14, 2020
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A ReviewMassimo Filippi, Paolo Preziosa, Frederik Barkhof, et al.
Nature Reviews. Neurology|January 13, 2021
Mind the gap: from neurons to networks to outcomes in multiple sclerosisDeclan T Chard, Adnan A S Alahmadi, Bertrand Audoin, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2019
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumabJ William L Brown, Ferran Prados Carrasco, Arman Eshaghi, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Trials|December 8, 2025
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapyGioia Riboni-Verri, Christopher E McMurran, Trisha Mukherjee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 9, 2020
Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosisRuth Geraldes, Maciej Juryńczyk, Giordani Dos Passos, et al.
Multiple Sclerosis and Related Disorders|February 8, 2018
Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosisÖzgür Yaldizli, Varun Sethi, Matteo Pardini, et al.
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2016
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosisMatteo Pardini, Carole H Sudre, Ferran Prados, et al.
JAMA Neurology|December 14, 2020
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A ReviewMassimo Filippi, Paolo Preziosa, Frederik Barkhof, et al.
Nature Reviews. Neurology|January 13, 2021
Mind the gap: from neurons to networks to outcomes in multiple sclerosisDeclan T Chard, Adnan A S Alahmadi, Bertrand Audoin, et al.
Pageof 8